This study is currently not recruiting participants.

Sample Collection Study Protocol: ALPCO Calprotectin ELISA

  • STATUS
    Not Recruiting
Updated on 19 February 2024

Summary

The clinical study will serve to confirm the sensitivity and specificity of the ALPCO ELISA as compared to gastroenterologist diagnosis (including colonoscopy results and other clinical information) in patients with signs and symptoms of IBS or IBD, using the proposed cut-off value (100 ~g/g) as an aid in differentiating between a diagnosis of an Inflammatory Bowel Disease and other non-inflammatory disorders, most notably Irritable Bowel Syndrome.

Description

The clinical study will serve to confirm the sensitivity and specificity of the ALPCO ELISA as compared to gastroenterologist diagnosis (including colonoscopy results and other clinical information) in patients with signs and symptoms of IBS or IBD, using the proposed cut-off value (100 ~g/g) as an aid in differentiating between a diagnosis of an Inflammatory Bowel Disease and other non-inflammatory disorders, most notably Irritable Bowel Syndrome.

Details
Condition inflammatory bowel disease,irritable bowel syndrome
Age 100years or below
Clinical Study IdentifierTX8563
Last Modified on19 February 2024

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.